[Results of percutaneous radiotherapy of bladder cancer using 1 and 2 series of irradiation].
In a randomized prospective clinical study, the authors investigate the results of percutaneous radiotherapy (telecobalt) with two rhythms of fractionation in patients with vesical carcinomas. A one-series irradiation with 1.5 Gy daily (except the weekends) up to a total dose of 60 Gy is compared to a two-series irradiation (in the first series 3 Gy three days per week up to 30 Gy, then irradiation-free interval of four weeks, in the second series 1.5 Gy daily up to a total focal dose of 60 Gy). The five-year survival rates are 52% after one-series irradiation and 39% after two-series irradiation. The surgical treatment consisted in a most radical resection of the vesical tumor by TUTUR, partial resection of the wall, of transvesical tumor resection.
D000368:Aged; D002986:Clinical Trials as Topic; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D011897:Random Allocation; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy* / Q000601:surgery
D003037:Cobalt Radioisotopes
Ergebnisse der perkutanen Strahlentherapie bei Harnblasenkarzinomen mit Einserien- und Zweiserienbestrahlung.